K Costello
Overview
Explore the profile of K Costello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smyth K, Affandi J, McArthur J, Bowtell-Harris C, Mijch A, Watson K, et al.
HIV Med
. 2007 Jul;
8(6):367-73.
PMID: 17661844
Objectives: The aim of the study was to describe the prevalence of and risk factors for HIV-associated sensory neuropathy (HIV-SN) in 2006 [the era of stavudine, didanosine and zalcitabine (dNRTI)-sparing...
2.
Valenzuela R, Costello K, Chen M, Said A, Johnson K, Dhib-Jalbut S
Mult Scler
. 2007 Jul;
13(6):754-62.
PMID: 17613604
Objective: To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-gamma and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS). Background: GA therapy involves the induction of anti-inflammatory...
3.
McKean M, Costello K, Scordato R, Ligugnana R
G Ital Med Lav Ergon
. 2005 Aug;
27(2):240-3.
PMID: 16124538
The use of manual pipettes has been associated with a high prevalence of upper extremity and neck cumulative trauma disorders (CTD's) and work-related musculoskeletal disorders (WMSD's) among laboratory workers. The...
4.
Pulicken M, Bash C, Costello K, Said A, Cuffari C, Wilterdink J, et al.
Mult Scler
. 2005 Mar;
11(2):169-74.
PMID: 15794390
We conducted an open-label pilot clinical trial to evaluate the safety and efficacy of adding oral azathioprine to the treatment regimen of 15 multiple sclerosis patients breaking through monotherapy with...
5.
Levy R, Rayner C, Fairley C, Kong D, Mijch A, Costello K, et al.
AIDS Patient Care STDS
. 2005 Jan;
18(12):728-35.
PMID: 15659884
Maintaining greater than 95% adherence to antiretroviral medication is necessary in order to have the greatest therapeutic impact on HIV infection. Furthermore, evidence suggests that adherence rates of between 70%...
6.
Fairley C, Levy R, Rayner C, Allardice K, Costello K, Thomas C, et al.
Int J STD AIDS
. 2003 Dec;
14(12):805-9.
PMID: 14678587
Our aim was to determine if a comprehensive adherence package improved self reported adherence to antiretroviral therapy. The adherence package included an education programme, individualized planning of regimens, and the...
7.
Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H
Mult Scler
. 2002 Dec;
8(6):485-91.
PMID: 12474988
The combined treatment with interferon beta (IFNbeta) and glatiramer acetate (GA) is of current interest in multiple sclerosis (MS). The therapeutic effect of GA in MS is believed to be...
8.
Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S
Mult Scler
. 2001 Sep;
7(4):209-19.
PMID: 11548979
Glatiromer acetate (GA) is an approved treatment for multiple sclerosis (MS). The proposed mechanism of action is the induction of GA-specific T cells characterized by protective anti-inflammatory Th2 response. We...
9.
10.
Costello K, Conway K
Rehabil Nurs
. 1997 Mar;
22(2):62-6, 81.
PMID: 9110845
In 1993, recombinant interferon beta-1b (Betaseron, Berlex Laboratories) was approved by the Food and Drug Administration as a treatment for relapsing-remitting multiple sclerosis (MS). Betaseron is the first therapeutic agent...